In this analysis, 42 patients with FLT3-mutated AML received azacitidine + venetoclax, and 22 patients had received azacitidine alone (all of whom were treated on the control arm of the VIALE-A study). This evidence concerns the gene FLT3 and acute myeloid leukemia.